• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

聚(ADP-核糖)聚合酶1(PARP1)在DNA损伤后修饰EZH2并抑制EZH2组蛋白甲基转移酶活性。

Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage.

作者信息

Caruso Lisa B, Martin Kayla A, Lauretti Elisabetta, Hulse Michael, Siciliano Micheal, Lupey-Green Lena N, Abraham Aaron, Skorski Tomasz, Tempera Italo

机构信息

Fels Institute for Cancer Research & Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.

Present address: The Wistar Institute, Philadelphia, PA, USA.

出版信息

Oncotarget. 2018 Jan 24;9(12):10585-10605. doi: 10.18632/oncotarget.24291. eCollection 2018 Feb 13.

DOI:10.18632/oncotarget.24291
PMID:29535829
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5828221/
Abstract

The enzyme Poly(ADP-ribose) polymerase 1 (PARP1) plays a very important role in the DNA damage response, but its role in numerous aspects is not fully understood. We recently showed that in the absence of DNA damage, PARP1 regulates the expression of the chromatin-modifying enzyme EZH2. Work from other groups has shown that EZH2 participates in the DNA damage response. These combined data suggest that EZH2 could be a target of PARP1 in both untreated and genotoxic agent-treated conditions. In this work we tested the hypothesis that, in response to DNA damage, PARP1 regulates EZH2 activity. Here we report that PARP1 regulates EZH2 activity after DNA damage. In particular, we find that EZH2 is a direct target of PARP1 upon induction of alkylating and UV-induced DNA damage in cells and . PARylation of EZH2 inhibits EZH2 histone methyltransferase (H3K27me) enzymatic activity. We observed in cells that the induction of PARP1 activity by DNA alkylating agents decreases the association of EZH2 with chromatin, and PARylation of histone H3 reduces EZH2 affinity for its target histone H3. Our findings establish that PARP1 and PARylation are important regulators of EZH2 function and link EZH2-mediated heterochromatin formation, DNA damage and PARylation. These findings may also have clinical implications, as they suggest that inhibitors of EZH2 can improve anti-tumor effects of PARP1 inhibitors in BRCA1/2-deficient cancers.

摘要

聚(ADP - 核糖)聚合酶1(PARP1)在DNA损伤反应中起着非常重要的作用,但其在众多方面的作用尚未完全明确。我们最近发现,在没有DNA损伤的情况下,PARP1可调节染色质修饰酶EZH2的表达。其他研究小组的工作表明,EZH2参与DNA损伤反应。这些综合数据表明,在未处理和经基因毒性剂处理的条件下,EZH2都可能是PARP1的作用靶点。在本研究中,我们验证了一个假设,即响应DNA损伤时,PARP1调节EZH2的活性。在此我们报告,DNA损伤后PARP1调节EZH2的活性。具体而言,我们发现,在细胞中诱导烷基化和紫外线诱导的DNA损伤后,EZH2是PARP1的直接靶点。EZH2的聚(ADP - 核糖)化抑制了EZH2组蛋白甲基转移酶(H3K27me)的酶活性。我们在细胞中观察到,DNA烷基化剂诱导PARP1活性会降低EZH2与染色质的结合,组蛋白H3的聚(ADP - 核糖)化降低了EZH2对其靶标组蛋白H3的亲和力。我们的研究结果表明,PARP1和聚(ADP - 核糖)化是EZH2功能的重要调节因子,并将EZH2介导的异染色质形成、DNA损伤和聚(ADP - 核糖)化联系起来。这些发现可能也具有临床意义,因为它们表明EZH2抑制剂可以提高PARP1抑制剂在BRCA1/2缺陷型癌症中的抗肿瘤效果。

相似文献

1
Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage.聚(ADP-核糖)聚合酶1(PARP1)在DNA损伤后修饰EZH2并抑制EZH2组蛋白甲基转移酶活性。
Oncotarget. 2018 Jan 24;9(12):10585-10605. doi: 10.18632/oncotarget.24291. eCollection 2018 Feb 13.
2
Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.定义 NSD2 相互作用组:PARP1 的 PAR 化降低 NSD2 组蛋白甲基转移酶活性并阻碍染色质结合。
J Biol Chem. 2019 Aug 16;294(33):12459-12471. doi: 10.1074/jbc.RA118.006159. Epub 2019 Jun 27.
3
Poly(ADP-ribosyl)ation of acetyltransferase NAT10 by PARP1 is required for its nucleoplasmic translocation and function in response to DNA damage.PARP1 对乙酰基转移酶 NAT10 的多聚(ADP-核糖基)化对于其核质易位以及在 DNA 损伤反应中的功能是必需的。
Cell Commun Signal. 2022 Aug 19;20(1):127. doi: 10.1186/s12964-022-00932-1.
4
Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2.全转录组分析表明聚(ADP-核糖)聚合酶1通过EZH2调节基因表达。
Mol Cell Biol. 2015 Dec;35(23):3934-44. doi: 10.1128/MCB.00635-15. Epub 2015 Sep 14.
5
MORC2 regulates DNA damage response through a PARP1-dependent pathway.MORC2 通过依赖 PARP1 的途径调节 DNA 损伤反应。
Nucleic Acids Res. 2019 Sep 19;47(16):8502-8520. doi: 10.1093/nar/gkz545.
6
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.聚 ADP-核糖聚合酶 1(PARP1)抑制剂作为抗癌药物的药物化学方法 - 最新进展。
Eur J Med Chem. 2019 Mar 1;165:198-215. doi: 10.1016/j.ejmech.2019.01.024. Epub 2019 Jan 12.
7
Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair.磷酸酶 1 核靶向亚基介导聚(ADP-核糖)聚合酶 1 在 DNA 修复中的募集和功能。
Cancer Res. 2019 May 15;79(10):2526-2535. doi: 10.1158/0008-5472.CAN-18-1673. Epub 2019 Feb 7.
8
The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.癌蛋白 DEK 影响轻度复制应激期间 PARP1/2 抑制的结果。
PLoS One. 2019 Aug 13;14(8):e0213130. doi: 10.1371/journal.pone.0213130. eCollection 2019.
9
Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor.利司多林 B 衍生物作为 PARP1 抑制剂的设计、合成与活性研究。
Bioorg Med Chem. 2022 Sep 1;69:116892. doi: 10.1016/j.bmc.2022.116892. Epub 2022 Jun 20.
10
Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.聚(ADP-核糖)聚合酶1和聚(ADP-核糖)在调节WRN和RECQL5活性中的差异作用与协同作用
Mol Cell Biol. 2015 Dec;35(23):3974-89. doi: 10.1128/MCB.00427-15. Epub 2015 Sep 21.

引用本文的文献

1
EZH2: An analysis of a potential new tumor marker in high-risk localization of cutaneous squamous cell carcinomas.EZH2:皮肤鳞状细胞癌高危定位中一种潜在新肿瘤标志物的分析
Front Oncol. 2025 Mar 11;14:1438021. doi: 10.3389/fonc.2024.1438021. eCollection 2024.
2
EZH2 directly methylates PARP1 and regulates its activity in cancer.EZH2 直接甲基化 PARP1 并调节其在癌症中的活性。
Sci Adv. 2024 Nov 29;10(48):eadl2804. doi: 10.1126/sciadv.adl2804. Epub 2024 Nov 27.
3
PARticular MARks: Histone ADP-ribosylation and the DNA damage response.

本文引用的文献

1
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.EZH2 通过其在乳腺癌中的 PARP 介导的聚 ADP 核糖基化作用促进对 PARP 抑制剂的反应。
Oncogene. 2018 Jan 11;37(2):208-217. doi: 10.1038/onc.2017.311. Epub 2017 Sep 18.
2
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.基因表达和突变引导的合成致死性可根除增殖期和静止期白血病细胞。
J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.
3
DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrity.
特殊标记:组蛋白 ADP-ribosylation 和 DNA 损伤反应。
DNA Repair (Amst). 2024 Aug;140:103711. doi: 10.1016/j.dnarep.2024.103711. Epub 2024 Jun 22.
4
PARP1 as an Epigenetic Modulator: Implications for the Regulation of Host-Viral Dynamics.聚(ADP-核糖)聚合酶1作为一种表观遗传调节剂:对宿主-病毒动态调节的影响
Pathogens. 2024 Jan 30;13(2):131. doi: 10.3390/pathogens13020131.
5
Exploring the interplay between PARP1 and circRNA biogenesis and function.探索聚(ADP - 核糖)聚合酶1(PARP1)与环状RNA生物合成及功能之间的相互作用。
Wiley Interdiscip Rev RNA. 2023 Nov 13:e1823. doi: 10.1002/wrna.1823.
6
Epigenetic Insights on PARP-1 Activity in Cancer Therapy.癌症治疗中PARP-1活性的表观遗传学见解
Cancers (Basel). 2022 Dec 20;15(1):6. doi: 10.3390/cancers15010006.
7
Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.PARP和EZH2联合抑制用于癌症治疗:现状、机遇与挑战
Front Pharmacol. 2022 Oct 3;13:965244. doi: 10.3389/fphar.2022.965244. eCollection 2022.
8
Role of NAD and FAD in Ischemic Stroke Pathophysiology: An Epigenetic Nexus and Expanding Therapeutic Repertoire.NAD 和 FAD 在缺血性中风病理生理学中的作用:一个表观遗传学枢纽和不断扩大的治疗谱。
Cell Mol Neurobiol. 2023 Jul;43(5):1719-1768. doi: 10.1007/s10571-022-01287-4. Epub 2022 Sep 30.
9
Neuroprotective Effects of PARP Inhibitors in Models of Alzheimer's Disease.聚腺苷二磷酸核糖聚合酶抑制剂在阿尔茨海默病模型中的神经保护作用。
Cells. 2022 Apr 9;11(8):1284. doi: 10.3390/cells11081284.
10
Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?表观遗传疗法在调节DNA损伤修复途径以增强化疗效果并克服耐药性方面是否发挥作用?
Cancers (Basel). 2022 Mar 16;14(6):1533. doi: 10.3390/cancers14061533.
DNA依赖蛋白激酶介导的EZH2磷酸化调节DNA损伤诱导的凋亡以维持T细胞基因组完整性。
Cell Death Dis. 2016 Jul 28;7(7):e2316. doi: 10.1038/cddis.2016.198.
4
The Polycomb Group Protein EZH2 Impairs DNA Damage Repair Gene Expression in Human Uterine Fibroids.多梳蛋白EZH2损害人类子宫肌瘤中DNA损伤修复基因的表达。
Biol Reprod. 2016 Mar;94(3):69. doi: 10.1095/biolreprod.115.134924. Epub 2016 Feb 17.
5
Poly(ADP-ribosyl)ation-dependent Transient Chromatin Decondensation and Histone Displacement following Laser Microirradiation.激光微照射后多聚(ADP - 核糖基)化依赖性的瞬时染色质解聚和组蛋白置换
J Biol Chem. 2016 Jan 22;291(4):1789-1802. doi: 10.1074/jbc.M115.694992. Epub 2015 Nov 11.
6
Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2.全转录组分析表明聚(ADP-核糖)聚合酶1通过EZH2调节基因表达。
Mol Cell Biol. 2015 Dec;35(23):3934-44. doi: 10.1128/MCB.00635-15. Epub 2015 Sep 14.
7
Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.染色质重塑因子CHD4的缺失使急性髓系白血病母细胞对基因毒性药物敏感,并减少肿瘤形成。
Blood. 2015 Sep 17;126(12):1462-72. doi: 10.1182/blood-2015-03-631606. Epub 2015 Aug 11.
8
A Systematic Analysis of Factors Localized to Damaged Chromatin Reveals PARP-Dependent Recruitment of Transcription Factors.对定位于受损染色质的因素进行的系统分析揭示了转录因子的PARP依赖性募集。
Cell Rep. 2015 Jun 9;11(9):1486-500. doi: 10.1016/j.celrep.2015.04.053. Epub 2015 May 21.
9
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.突变型 BRCA1 蛋白的稳定导致聚腺苷二磷酸核糖聚合酶抑制剂和铂类耐药。
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1.
10
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.口服聚(ADP-核糖)聚合酶(PARP)抑制剂奥拉帕利联合紫杉醇用于转移性三阴性乳腺癌患者一线或二线治疗的I期试验。
Breast Cancer Res. 2013;15(5):R88. doi: 10.1186/bcr3484.